A phase I trial of ornithine phenylacetate (OCR-002) for hepatic encephalopathy in patients with cirrhosis

Trial Profile

A phase I trial of ornithine phenylacetate (OCR-002) for hepatic encephalopathy in patients with cirrhosis

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Ornithine phenylacetate (Primary) ; Ornithine phenylacetate (Primary)
  • Indications Hepatic encephalopathy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 23 Aug 2017 According to an Ocera Therapeutics media release, data from this trial will be presented at the 68th Annual Meeting of the American Association for the Study of Liver Disease (AASLD).
    • 05 Jan 2017 Status changed from recruiting to completed, according to an Ocera Therapeutics media release.
    • 05 Jan 2017 Results published in an Ocera Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top